CONMED (NYSE:CNMD – Get Free Report) and LivaNova (NASDAQ:LIVN – Get Free Report) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.
Analyst Ratings
This is a summary of current ratings and recommmendations for CONMED and LivaNova, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CONMED | 0 | 1 | 4 | 0 | 2.80 |
| LivaNova | 0 | 4 | 2 | 0 | 2.33 |
CONMED currently has a consensus price target of $135.67, indicating a potential upside of 40.35%. LivaNova has a consensus price target of $65.00, indicating a potential upside of 25.68%. Given CONMED’s stronger consensus rating and higher possible upside, equities research analysts plainly believe CONMED is more favorable than LivaNova.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| CONMED | 7.75% | 11.14% | 3.61% |
| LivaNova | -8.94% | 11.60% | 6.12% |
Risk & Volatility
CONMED has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
Institutional & Insider Ownership
97.6% of LivaNova shares are held by institutional investors. 7.6% of CONMED shares are held by insiders. Comparatively, 0.2% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares CONMED and LivaNova’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CONMED | $1.05 billion | 2.84 | -$80.58 million | $2.83 | 34.16 |
| LivaNova | $1.02 billion | 2.73 | -$86.25 million | ($1.82) | -28.42 |
CONMED has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.
Summary
CONMED beats LivaNova on 11 of the 14 factors compared between the two stocks.
About CONMED
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
About LivaNova
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.
